Key Points
-
Shopify’s stock has declined 40% since its peak in October 2022 due to slowed sales growth and rising interest rates.
-
Nice Ltd, a customer service automation company, reported a 66% year-over-year increase in recurring revenue, reaching an annualized run rate of $345 million as of Q1 2026.
-
Viking Therapeutics is in phase 3 trials with its GLP-1 weight-loss drug, VK2735, which has the potential to disrupt the $200 billion obesity drug market by 2035.
Shopify (NASDAQ: SHOP) has seen a significant drop in stock value, falling 40% from its October peak due to concerns over market conditions and competition. Despite these fears, the company’s revenue growth accelerated to 34% in Q1 2026, raising questions about the extent of market pessimism about its future outlook.
Nice Ltd (NASDAQ: NICE) has been leveraging artificial intelligence to enhance its customer service technology, facilitating over 20 billion interactions annually for major clients like Disney and PayPal. The company’s cloud revenue, which constitutes a significant portion of its earnings, grew notably in Q1 2026, indicating a strong growth trajectory in its automation services.
Viking Therapeutics (NASDAQ: VKTX) is advancing in the competitive weight-loss drug market with its dual agonist VK2735, currently in phase 3 trials. Analysts remain optimistic, projecting a price target of $95.40, representing a potential 200% increase as the company aims to penetrate a market projected to reach $200 billion by 2035.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
